Abiopharma

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

New Form S-3 - Dominari Holdings Inc. Filed: 2025-08-28 AccNo: 0001213900-25-081384 Size: 755 KB

Merus to Present at the 2025 Wells Fargo Healthcare Conference

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

Collegium to Participate in Upcoming Investor Conferences

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

GE HealthCare showcases integrated cardiology care pathway solutions and new AI-driven innovations at ESC 2025

Akebia Therapeutics to Present at Upcoming Investor Conferences

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference

Natera - Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer